These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 3575249)

  • 1. Displacement of lidocaine from human plasma proteins by disopyramide.
    Bonde J; Jensen NM; Burgaard P; Angelo HR; Graudal N; Kampmann JP; Pedersen LE
    Pharmacol Toxicol; 1987 Feb; 60(2):151-5. PubMed ID: 3575249
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Suppression of ventricular arrhythmias with intravenous disopyramide and lidocaine: efficacy comparison in a randomized trial.
    Sbarbaro JA; Rawling DA; Fozzard HA
    Am J Cardiol; 1979 Sep; 44(3):513-20. PubMed ID: 474432
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Factors influencing serum protein binding of lidocaine in humans.
    McNamara PJ; Slaughter RL; Pieper JA; Wyman MG; Lalka D
    Anesth Analg; 1981 Jun; 60(6):395-400. PubMed ID: 6165258
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Concentration-dependence of disopyramide binding to plasma protein and its influence on kinetics and dynamics.
    Lima JJ; Boudoulas H; Blanford M
    J Pharmacol Exp Ther; 1981 Dec; 219(3):741-7. PubMed ID: 7299695
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relationship between alpha 1-acid glycoprotein and distribution of disopyramide and mono-N-dealkyldisopyramide in whole blood.
    Bredesen JE; Kierulf P
    Br J Clin Pharmacol; 1986 Sep; 22(3):281-6. PubMed ID: 3768240
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Protein binding of disopyramide--displacement by mono-N-dealkyldisopyramide and variation with source of alpha-1-acid glycoprotein.
    Haughey DB; Steinberg I; Lee MH
    J Pharm Pharmacol; 1985 Apr; 37(4):285-8. PubMed ID: 2860235
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasma protein binding of disopyramide by equilibrium dialysis and ultrafiltration.
    David BM; Tjokrosetio R; Ilett KF
    Ther Drug Monit; 1983; 5(1):81-6. PubMed ID: 6845403
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Binding characteristics of KNI-272 to plasma proteins, a new potent tripeptide HIV protease inhibitor.
    Kiriyama A; Nishiura T; Ishino M; Yamamoto Y; Ogita I; Kiso Y; Takada K
    Biopharm Drug Dispos; 1996 Dec; 17(9):739-51. PubMed ID: 8968527
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Binding of disopyramide to alpha 1-acid glycoprotein in plasma measured by competitive equilibrium dialysis.
    Norris RL; Ahokas JT; Ravenscroft PJ; Henry M
    J Pharm Sci; 1984 Jun; 73(6):824-6. PubMed ID: 6737271
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nomogram for estimating plasma unbound disopyramide concentrations in patients with varying plasma alpha 1-acid glycoprotein concentrations.
    Echizen H; Ishikawa S; Koike K; Ishizaki T
    Ther Drug Monit; 1995 Apr; 17(2):145-52. PubMed ID: 7624903
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasma protein binding of disopyramide in pregnant and postpartum women, and in neonates and their mothers.
    Echizen H; Nakura M; Saotome T; Minoura S; Ishizaki T
    Br J Clin Pharmacol; 1990 Apr; 29(4):423-30. PubMed ID: 2183867
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of intra-individual change in serum protein binding on the pharmacologic response of R- and S-disopyramide in the rabbit.
    Huang JD; Oie S
    Res Commun Chem Pathol Pharmacol; 1983 Aug; 41(2):243-53. PubMed ID: 6635319
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protein binding of disopyramide and elevated alpha-1-acid glycoprotein concentrations in serum obtained from dialysis patients and renal transplant recipients.
    Haughey DB; Kraft CJ; Matzke GR; Keane WF; Halstenson CE
    Am J Nephrol; 1985; 5(1):35-9. PubMed ID: 3881959
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Changes in the binding capacity of alpha-1-acid glycoprotein in patients with renal insufficiency.
    Kishino S; Nomura A; Di ZS; Sugawara M; Iseki K; Kakinoki S; Kitabatake A; Miyazaki K
    Ther Drug Monit; 1995 Oct; 17(5):449-53. PubMed ID: 8585106
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immediate- versus controlled-release disopyramide: importance of saturable binding.
    Davies RF; Siddoway LA; Shaw L; Barbey JT; Roden DM; Woosley RL
    Clin Pharmacol Ther; 1993 Jul; 54(1):16-22. PubMed ID: 8330460
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The acute changes in serum binding of disopyramide and flecainide after myocardial infarction.
    Caplin JL; Johnston A; Hamer J; Camm AJ
    Eur J Clin Pharmacol; 1985; 28(3):253-5. PubMed ID: 4007029
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alpha-1-acid glycoprotein concentration and the protein binding of disopyramide in healthy subjects.
    Kishino S; Nomura A; Di ZS; Sugawara M; Iseki K; Kakinoki S; Kitabatake A; Miyazaki K
    J Clin Pharmacol; 1995 May; 35(5):510-4. PubMed ID: 7657852
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A HPLC method for the simultaneous determination of disopyramide, lidocaine and their monodealkylated metabolites.
    Angelo HR; Bonde J; Kampmann JP; Kastrup J
    Scand J Clin Lab Invest; 1986 Nov; 46(7):623-7. PubMed ID: 3787162
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Displacement of disopyramide from human plasma proteins.
    Pedersen LE; Bonde J
    Acta Pharmacol Toxicol (Copenh); 1985 Sep; 57(3):223-6. PubMed ID: 4061102
    [No Abstract]   [Full Text] [Related]  

  • 20. Interaction of disopyramide enantiomers for sites on plasma protein.
    Lima JJ
    Life Sci; 1987 Dec; 41(26):2807-13. PubMed ID: 3695808
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.